Search Results

April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal (Strasbourg, France; CEO: Pascal Neuville; “Domain”) and Université de Montréal (Québec, Canada; “UdM

Professor in the Department of Biochemistry and Molecular Medicine of the Faculty of Medicine of the Université de Montréal, is appointed Knight of the Ordre national du Québec.

Tim De Groof! It’s not often when you get the best of both worlds - nano-bodies and #GPCRs.

Michel Bouvier received the title of Doctor Honoris Causa from the Université de Montpellier Domain Therapeutics

This is the essence of de-risking GPCR programs through operational excellence. your drug discovery process from a series of disconnected efforts into a seamless, predictable, and de-risked Learn to translate your program’s internal operational precision into a compelling, de-risked narrative

A postdoc in Santiago de Compostela introduced her to GPCRs, and from there, things escalated quickly

conversation dives deep into the tools now transforming receptor biology—and how they’re being used to de-orphanize

Member Profile Antony Boucard Professor Centro de Investigación y de Estudios Avanzados del IPN (Cinvestav AB: Favorite Taco: Taco de suadero (pronounced swa-day-ro), fatty, with meat caramelized in its own fat

Boston, MA and Santiago de Compostela, Spain — [June 3rd, 2025]  — Dr.

GPCR consulting that cuts through the noise, designing assay cascades, setting go/no-go points, and de-risking

Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris De

package assist in the launch of Phase 2 clinical development Metabolic disorders are a global epidemic1 MONTREAL

clinical development of its best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL

Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial "MONTREAL

  Madelyn N Moore , Kelsey L Person , Abigail Alwin , Campbell Krusemark , Ezequiel Marron Fernandez de loss after a year, with no plateau INAUGURATION OF AELIS FARMA NEW LABORATORY at Institut Européen de

May 2022 "MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc.

.; Henry De Villeneuve, C.; Moraillon, A.; Ozanam, F.; Gabouze, N.; Djebbar, S.

Your pipeline depends on early, well-informed decisions that move promising candidates forward while de-prioritizing

Fluorescence Microscopy validation performed in the ONCOMET laboratory (Health Research Institute of Santiago de

Emerging direction: Treatment sequencing + guided de-escalation.

Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris De

L, González A, Gioé-Gallo C, Mallo-Abreu A, Brea J, Loza MI, García-Rey A, García-Mera X, Gutiérrez-de-Terán

De novo drug design: AI algorithms can generate new molecules with desired properties, such as binding chemical space, limiting their ability to identify truly novel chemotypes”(Thomas, Smith, O’Boyle, de

running early-stage programs, recognizing this decoupling early can sharpen dose optimization  and de-risk

Domain Therapeutics was nominated for the Trophée de l'Innovation Technologique (Technological Innovation

Therefore, matching a ligand to an orphan GPCRs, the process of de-orphanizing, is of great importance

This week's highlight includes congrats to Omolade Otun, Chris de Graaf, Cherine Bechara, et al. for

✅ The sooner you understand what they’re optimizing for, the faster you can align your strategy to de-risk

GPCR drugmaker Septerna amasses $288M in IPO Surrounded by AI bio giants, tiny startup Nabla Bio makes de

Learn how to transform your program from a series of disconnected efforts into a predictable, de-risked